已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies

阿替唑单抗 彭布罗利珠单抗 无容量 阿维鲁单抗 医学 肿瘤科 肺癌 内科学 危险系数 荟萃分析
作者
Maofen Jiang,Chunjiao Liu,Dongxiao Ding,Hui Tian,Chaoqun Yu
出处
期刊:Frontiers in Oncology [Frontiers Media]
卷期号:12
标识
DOI:10.3389/fonc.2022.827050
摘要

Objective The present network meta-analysis (NMA) was conducted to summarize the direct and indirect evidence of common programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors including avelumab, atezolizumab, cemiplimab, nivolumab, and pembrolizumab for the treatment of non-small cell lung cancer (NSCLC) patients and further to determine the optimal therapeutic regimen. Methods We performed a systematic literature search to identify all potentially eligible studies in PubMed, Embase, and the Cochrane Library until August 7, 2021. The primary outcome was overall survival (OS), and the second outcome was treatment-related adverse events (TRAEs). We used random-effects model to conduct direct and network meta-analyses, which were performed by using RevMan 5.3 and R version 3.6.1, respectively. Results Direct meta-analysis suggested that atezolizumab, cemiplimab, nivolumab, or pembrolizumab significantly improved OS compared with chemotherapy (CT), and NMA further established that atezolizumab [hazard ratio (HR), 0.77; 95% CrI, 0.62–0.96], nivolumab (HR, 0.75; 95% CrI, 0.62–0.93), or pembrolizumab (HR, 0.71; 95% Credible interval (Crl), 0.57–0.89) significantly and cemiplimab (HR, 0.68; 95% CrI, 0.46–1.02) numerically improved OS compared with CT. Meanwhile, NMA also indicated that cemiplimab was numerically superior to other PD-1/PD-L1 agents. Moreover, avelumab, atezolizumab, cemiplimab, nivolumab, and pembrolizumab were found to have fewer TRAEs compared with CT in direct meta-analysis, which were supported by the results from the NMA. Meanwhile, surface under the cumulative ranking curve (SUCRA) and ranking probability suggested that cemiplimab provided the most favorable balance between efficacy and safety, with the first ranking for the OS. Conclusions Based on available evidence, cemiplimab may have the most favorable risk–benefit ratio for NSCLC patients compared with other common therapeutic management. However, future research with a large-scale, high-quality, and mature follow-up is needed to further determine which agents should be preferentially selected for NSCLC patients due to the limitations of our NMA and variations of eligible studies in treatment line and PD-L1 status.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
晞染完成签到,获得积分10
刚刚
谷谷发布了新的文献求助10
刚刚
852的应助被娇情儿采纳,获得10
1秒前
儒雅海亦完成签到 ,获得积分10
2秒前
3秒前
dyhhh发布了新的文献求助10
4秒前
TheAnt完成签到,获得积分10
4秒前
ZHOU完成签到,获得积分10
5秒前
强健的问芙完成签到 ,获得积分10
5秒前
5秒前
尾巴完成签到,获得积分10
5秒前
6秒前
6秒前
7秒前
8秒前
TheAnt发布了新的文献求助10
8秒前
脑洞疼的应助被可爱的鬼神采纳,获得50
8秒前
热心王友发布了新的文献求助10
8秒前
Imin完成签到,获得积分20
10秒前
ZHOU发布了新的文献求助10
11秒前
zhenzheng完成签到 ,获得积分0
11秒前
十四发布了新的文献求助10
11秒前
11秒前
伯赏迎松发布了新的文献求助30
12秒前
komorebi发布了新的文献求助10
12秒前
moriaty发布了新的文献求助200
13秒前
13秒前
13秒前
Lucas的应助被犽狸采纳,获得10
14秒前
Xhn发布了新的文献求助10
14秒前
15秒前
娇情儿发布了新的文献求助10
16秒前
18秒前
东榆桑榆发布了新的文献求助10
18秒前
一只大嵩鼠完成签到 ,获得积分10
19秒前
良仔完成签到,获得积分10
19秒前
今后的应助被waituu采纳,获得10
20秒前
彭于晏的应助被杨杨采纳,获得10
20秒前
被风吹过的路的应助被2436698119采纳,获得10
21秒前
纯情的阁发布了新的文献求助10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165423
求助须知:如何正确求助?哪些是违规求助? 9559005
关于积分的说明 21748579
捐赠科研通 7756086
什么是DOI,文献DOI怎么找? 3428919
关于科研通互助平台的介绍 2553193
邀请新用户注册赠送积分活动 2473473